Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours
Abstract
:Simple Summary
Abstract
1. Introduction
- ratings of acceptability (including, attitudes, opinions, beliefs, feelings, barriers or facilitators) by primary care providers with respect to (1) breast cancer risk assessment and (2) primary prevention advice
- the performance of routine behaviours by primary care providers regarding (1) breast cancer risk assessment and (2) primary prevention advice
- sources of variation in acceptability and behaviours
2. Methods
2.1. Search Strategy
2.2. Eligibility Criteria
- Healthcare professionals who provided primary care services. To account for variation in professional roles between healthcare structures in different countries, samples reported as being primary care providers were regarded as such. In ambiguous cases, authors were contacted to clarify whether their samples provided primary care services in line with the World Health Organisation’s definition [28].Studies conducted with both primary and secondary care providers were only included if it was possible to separately identify those findings relevant to primary care providers.
- Data had to be reported about risk assessment and/or providing primary prevention advice in the context of breast cancer. Studies focusing on cancer risk or primary prevention whereby data specific to breast cancer could not be extracted were excluded.
- Either or both of the following:
- (a)
- Acceptability defined as anticipated or experiential cognitive and emotional responses. Studies had to report one or more of the following outcomes using quantitative methodologies: attitudes, opinions (e.g., perceptions of responsibility), beliefs, feelings (e.g., confidence), barriers or facilitators.
- (b)
- Routine behaviours defined as typical or regular activity in clinical practice. Frequency of behaviours reported in a specific timeframe were not eligible for inclusion. Hypothetical clinical scenarios/vignettes or reflections on previous clinical cases were ineligible as these methods ascertain the action taken in a specific situation which may not be indicative of routine behaviours.
- Studies: Full empirical articles of any quantitative design published in the English language. Grey literature including PhD theses, dissertations and unpublished research were eligible for inclusion. Additionally, baseline surveys of intervention studies designed to improve breast cancer risk assessment behaviours or provision of primary prevention advice were included.
2.3. Selection and Coding of Studies
2.4. Data Extraction
2.5. Quality Assessment
2.6. Synthesis of the Evidence
3. Results
3.1. Study Characteristics
3.2. Perceived Practice Responsibilities with Respect to Both Risk Assessment and Primary Prevention
4. Risk Assessment
4.1. Barriers and Facilitators
4.2. Perceived Confidence
4.3. Routine Behaviours
5. Primary Prevention Advice
5.1. Barriers and Facilitators
5.2. Perceived Confidence and Routine Behaviours
5.3. Quality Assessment
6. Discussion
6.1. Summary of Main Findings
6.2. Relevance to Existing Literature
6.3. Limitations
6.4. Implications and Future Research Directions
7. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Autier, P.; Boniol, M. Mammography screening: A major issue in medicine. Eur. J. Cancer 2018, 90, 34–62. [Google Scholar] [CrossRef]
- Marmot, M.G.; Altman, D.; Cameron, D.; Dewar, J.; Thompson, S.; Wilcox, M. The benefits and harms of breast cancer screening: An independent review. Br. J. Cancer 2013, 108, 2205–2240. [Google Scholar] [CrossRef] [Green Version]
- Nelson, H.D.; Fu, R.; Cantor, A.; Pappas, M.; Daeges, M.; Humphrey, L. Effectiveness of breast cancer screening: Systematic review and meta-analysis to update the 2009 US Preventive Services Task Force recommendation. Ann. Intern. Med. 2016, 164, 244–255. [Google Scholar] [CrossRef] [PubMed]
- Brodersen, J.; Schwartz, L.M.; Heneghan, C.; O’Sullivan, J.W.; Aronson, J.K.; Woloshin, S. Overdiagnosis: What it is and what it isn’t. BMJ Evid. Based Med. 2018, 23, 1–3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mandrik, O.; Zielonke, N.; Meheus, F.; Severens, J.; Guha, N.; Herrero Acosta, R.; Murillo, R. Systematic reviews as a ‘lens of evidence’: Determinants of benefits and harms of breast cancer screening. Int. J. Cancer 2019, 145, 994–1006. [Google Scholar] [CrossRef] [Green Version]
- Pashayan, N.; Morris, S.; Gilbert, F.J.; Pharoah, P.D. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: A life-table model. JAMA Oncol. 2018, 4, 1504–1510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gail, M.H.; Brinton, L.A.; Byar, D.P.; Corle, D.K.; Green, S.B.; Schairer, C.; Mulvihill, J.J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. 1989, 81, 1879–1886. [Google Scholar] [CrossRef] [PubMed]
- Tyrer, J.; Duffy, S.W.; Cuzick, J. A breast cancer prediction model incorporating familial and personal risk factors. Stat. Med. 2004, 23, 1111–1130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Evans, D.G.; Astley, S.; Stavrinos, P.; Harkness, E.; Donnelly, L.S.; Dawe, S.; Jacob, I.; Harvie, M.; Cuzick, J.; Brentnall, A. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: A dual cohort study. Program. Grants Appl. Res. 2016, 4, 1–210. [Google Scholar] [CrossRef] [Green Version]
- Pashayan, N.; Antoniou, A.C.; Ivanus, U.; Esserman, L.J.; Easton, D.F.; French, D.; Sroczynski, G.; Hall, P.; Cuzick, J.; Evans, D.G.; et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat. Rev. Clin. Oncol. 2020, 17, 687–705. [Google Scholar] [CrossRef] [PubMed]
- Evans, D.G.R.; Donnelly, L.S.; Harkness, E.F.; Astley, S.M.; Stavrinos, P.; Dawe, S.; Watterson, D.; Fox, L.; Sergeant, J.C.; Ingham, S. Breast cancer risk feedback to women in the UK NHS breast screening population. Br. J. Cancer 2016, 114, 1045–1052. [Google Scholar] [CrossRef]
- Delaloge, S.; Gorgio-Rossi, P.; Balleyguier, C.; Guindy, M.; Burrion, J.B.; Gilbert, F. My Personal Breast Screening (MyPeBS). Available online: https://www.mypebs.eu/ (accessed on 12 April 2021).
- Esserman, L.J. The WISDOM Study: Breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer 2017, 3, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cuzick, J.; Sestak, I.; Bonanni, B.; Costantino, J.P.; Cummings, S.; DeCensi, A.; Dowsett, M.; Forbes, J.F.; Ford, L.; LaCroix, A.Z. Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data. Lancet 2013, 381, 1827–1834. [Google Scholar] [CrossRef] [Green Version]
- Cuzick, J.; Sestak, I.; Cawthorn, S.; Hamed, H.; Holli, K.; Howell, A.; Forbes, J.F.; Investigators, I.-I. Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015, 16, 67–75. [Google Scholar] [CrossRef]
- Parkin, D.M.; Boyd, L.; Walker, L. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br. J. Cancer 2011, 105, S77–S81. [Google Scholar] [CrossRef] [Green Version]
- National Institute for Health and Care Excellence. Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast Cancer [updated 2019 November] (Clinical Guideline [CG164]) 2013. Available online: https://www.nice.org.uk/guidance/cg164 (accessed on 12 October 2020).
- Dent, T.; Jbilou, J.; Rafi, I.; Segnan, N.; Törnberg, S.; Chowdhury, S.; Hall, A.; Lyratzopoulos, G.; Eeles, R.; Eccles, D. Stratified cancer screening: The practicalities of implementation. Public Health Genom. 2013, 16, 94–99. [Google Scholar] [CrossRef]
- Rainey, L.; van der Waal, D.; Jervaeus, A.; Wengström, Y.; Evans, D.G.; Donnelly, L.S.; Broeders, M.J. Are we ready for the challenge of implementing risk-based breast cancer screening and primary prevention? Breast 2018, 39, 24–32. [Google Scholar] [CrossRef]
- Phillips, K.-A.; Steel, E.J.; Collins, I.; Emery, J.; Pirotta, M.; Mann, G.B.; Butow, P.; Hopper, J.L.; Trainer, A.; Moreton, J. Transitioning to routine breast cancer risk assessment and management in primary care: What can we learn from cardiovascular disease? Aust. J. Prim. Health 2016, 22, 255–261. [Google Scholar] [CrossRef]
- Public Health England. NHS Health Check Programme Best Practice Guidance 2019. Available online: https://www.healthcheck.nhs.uk/commissioners-and-providers/national-guidance/ (accessed on 20 October 2020).
- Skivington, K.; Matthews, L.; Simpson, S.A.; Craig, P.; Baird, J.; Blazeby, J.; Boyd, K.; Craig, N.; French, D.; McIntosh, E.; et al. Framework for the development and evaluation of complex interventions: Gap analysis, workshop and consultation-informed update. Health Technol. Assess. 2021, in press. [Google Scholar]
- Sekhon, M.; Cartwright, M.; Francis, J.J. Acceptability of health care interventions: A theoretical framework and proposed research agenda. Br. J. Health Psychol. 2018, 23, 519–531. [Google Scholar] [CrossRef]
- Hamilton, J.G.; Abdiwahab, E.; Edwards, H.M.; Fang, M.-L.; Jdayani, A.; Breslau, E.S. Primary care providers’ cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda. J. Gen. Intern. Med. 2017, 32, 315–324. [Google Scholar] [CrossRef] [PubMed]
- Mikat-Stevens, N.A.; Larson, I.A.; Tarini, B.A. Primary-care providers’ perceived barriers to integration of genetics services: A systematic review of the literature. Genet. Med. 2015, 17, 169–176. [Google Scholar] [CrossRef] [Green Version]
- Scheuner, M.T.; Sieverding, P.; Shekelle, P.G. Delivery of Genomic Medicine for Common Chronic Adult Diseases: A Systematic Review. JAMA 2008, 299, 1320–1334. [Google Scholar] [CrossRef]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Moher, D. Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement. J. Clin. Epidemiol. 2021, 134, 103–112. [Google Scholar] [CrossRef]
- World Health Organisation. Main Terminology. Available online: https://www.euro.who.int/en/health-topics/Health-systems/primary-health-care/main-terminology (accessed on 20 October 2020).
- Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—A web and mobile app for systematic reviews. Syst. Rev. 2016, 5, 210:1–210:10. [Google Scholar] [CrossRef] [Green Version]
- Hong, Q.N.; Fàbregues, S.; Bartlett, G.; Boardman, F.; Cargo, M.; Dagenais, P.; Gagnon, M.-P.; Griffiths, F.; Nicolau, B.; O’Cathain, A.; et al. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Educ. Inf. 2018, 34, 285–291. [Google Scholar] [CrossRef] [Green Version]
- Sabatino, S.A.; McCarthy, E.P.; Phillips, R.S.; Burns, R.B. Breast cancer risk assessment and management in primary care: Provider attitudes, practices, and barriers. Cancer Detect. Prev. 2007, 31, 375–383. [Google Scholar] [CrossRef] [PubMed]
- Petticrew, M.; Roberts, H. Systematic Reviews in the Social Sciences: A Practical Guide; Blackwell: Oxford, UK, 2006. [Google Scholar]
- Saunders-Goldson, S. A Web-Based Education Intervention on Breast Cancer Risk Assessment of Indigent Women in Primary Care. ABNF J. 2018, 29, 106–111. [Google Scholar]
- Carroll, J.C.; Wilson, B.J.; Allanson, J.; Grimshaw, J.; Blaine, S.M.; Meschino, W.S.; Permaul, J.A.; Graham, I.D. GenetiKit: A randomized controlled trial to enhance delivery of genetics services by family physicians. Fam. Pract. 2011, 28, 615–623. [Google Scholar] [CrossRef] [PubMed]
- Casas, R.S.; Ramachandran, A.; Gunn Christine, M.; Weinberg Janice, M.; Shaffer, K. Explaining Breast Density Recommendations: An Introductory Workshop for Breast Health Providers. MedEdPORTAL 2017, 13, 10654. [Google Scholar] [CrossRef]
- Mainous, A.G., 3rd; Johnson, S.P.; Chirina, S.; Baker, R. Academic family physicians’ perception of genetic testing and integration into practice: A CERA study. Fam. Med. 2013, 45, 257–262. [Google Scholar] [PubMed]
- Nippert, I.; Julian-Reynier, C.; Harris, H.; Evans, G.; van Asperen, C.J.; Tibben, A.; Schmidtke, J. Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: General practitioners’ and breast surgeons’ current practice and preferred practice responsibilities. J. Community Genet. 2014, 5, 69–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Escher, M.; Sappino, A.P. Primary care physicians’ knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann. Oncol. 2000, 11, 1131–1136. [Google Scholar] [CrossRef]
- Pichert, G.; Dietrich, D.; Moosmann, P.; Zwahlen, M.; Stahel, R.A.; Sappino, A.P. Swiss primary care physicians’ knowledge, attitudes and perception towards genetic testing for hereditary breast cancer. Fam. Cancer 2003, 2, 153–158. [Google Scholar] [CrossRef]
- Gunn, C.M.; Kressin, N.R.; Cooper, K.; Marturano, C.; Freund, K.M.; Battaglia, T.A. Primary Care Provider Experience with Breast Density Legislation in Massachusetts. J. Women’s Health 2018, 27, 615–622. [Google Scholar] [CrossRef]
- Macdonald, C.; Saunders, C.M.; Keogh, L.A.; Hunter, M.; Mazza, D.; McLachlan, S.A.; Jones, S.C.; Nesci, S.; Friedlander, M.L.; Hopper, J.L.; et al. Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians. Cancer Prev. Res. 2021, 14, 131–144. [Google Scholar] [CrossRef] [PubMed]
- Bankhead, C.; Emery, J.; Qureshi, N.; Campbell, H.; Austoker, J.; Watson, E. New developments in genetics-knowledge, attitudes and information needs of practice nurses. Fam. Pract. 2001, 18, 475–486. [Google Scholar] [CrossRef] [Green Version]
- Summerton, N.; Garrood, P.V. The family history in family practice: A questionnaire study. Fam. Pract. 1997, 14, 285–288. [Google Scholar] [CrossRef] [Green Version]
- Corbelli, J.; Borrero, S.; Bonnema, R.; McNamara, M.; Kraemer, K.; Rubio, D.; Karpov, I.; McNeil, M. Use of the Gail model and breast cancer preventive therapy among three primary care specialties. J. Women’s Health 2014, 23, 746–752. [Google Scholar] [CrossRef]
- Samimi, G.; Heckman-Stoddard, B.M.; Holmberg, C.; Tennant, B.; Sheppard, B.B.; Coa, K.I.; Kay, S.S.; Ford, L.G.; Szabo, E.; Minasian, L.M. Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians. Cancer Prev. Res. 2021, 14, 205–214. [Google Scholar] [CrossRef]
- Bidassie, B.; Kovach, A.; Vallette, M.A.; Merriman, J.; Park, Y.A.; Aggarwal, A.; Colonna, S. Breast Cancer Risk Assessment and Chemoprevention Use Among Veterans Affairs Primary Care Providers: A National Online Survey. Mil. Med. 2020, 185, 512–518. [Google Scholar] [CrossRef] [PubMed]
- Khong, K.A.; Hargreaves, J.; Aminololama-Shakeri, S.; Lindfors, K.K. Impact of the California Breast Density Law on Primary Care Physicians. J. Am. Coll. Radiol. 2015, 12, 256–260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maimone, S.; McDonough, M.D.; Hines, S.L. Breast Density Reporting Laws and Supplemental Screening—A Survey of Referring Providers’ Experiences and Understanding. Curr. Probl. Diagn. Radiol. 2017, 46, 105–109. [Google Scholar] [CrossRef]
- Edwards, Q.T.; Maradiegue, A.; Seibert, D.; Saunders-Goldson, S.; Humphreys, S. Breast cancer risk elements and nurse practitioners’ knowledge, use, and perceived comfort level of breast cancer risk assessment. J. Am. Assoc. Nurse Pract. 2009, 21, 270–277. [Google Scholar] [CrossRef] [PubMed]
- Tighe, M.-K. An Examination of Canadian Family Physicians’ Knowledge and Practice Patterns Regarding Breast Cancer Prevention. Master’s Thesis, Queen’s University, Kingston, ON, Canada, August 2009. [Google Scholar]
- Guerra, C.E.; Sherman, M.; Armstrong, K. Diffusion of Breast Cancer Risk Assessment in Primary Care. J. Am. Board Fam. Med. 2009, 22, 272–279. [Google Scholar] [CrossRef] [PubMed]
- Welkenhuysen, M.; Evers-Kiebooms, G. General practitioners and predictive genetic testing for late-onset diseases in Flanders: What are their opinions and do they want to be involved? Community Genet. 2002, 5, 128–137. [Google Scholar] [CrossRef]
- Bethea, J.; Qureshi, N.; Drury, N.; Guilbert, P. The impact of genetic outreach education and support to primary care on practitioner’s confidence and competence in dealing with familial cancers. Community Genet. 2008, 11, 289–294. [Google Scholar] [CrossRef]
- Wilson, B.J.; Torrance, N.; Mollison, J.; Watson, M.S.; Douglas, A.; Miedzybrodzka, Z.; Gordon, R.; Wordsworth, S.; Campbell, M.; Haites, N.; et al. Cluster randomized trial of a multifaceted primary care decision-support intervention for inherited breast cancer risk. Fam. Pract. 2006, 23, 537–544. [Google Scholar] [CrossRef]
- Dekanek, E.W.; Thull, D.L.; Massart, M.; Grubs, R.E.; Rajkovic, A.; Mai, P.L. Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians. J. Genet. Couns. 2020, 29, 122–130. [Google Scholar] [CrossRef]
- Hall, P.H. Documentation of Breast Cancer Family History in Primary Care. Master’s Thesis, University of Minnesota, Minneapolis, MN, USA, January 2001. [Google Scholar]
- Walter, F.M.; Kinmonth, A.L.; Hyland, F.; Murrell, P.; Marteau, T.M.; Todd, C. Experiences and expectations of the new genetics in relation to familial risk of breast cancer: A comparison of the views of GPs and practice nurses. Fam. Pract. 2001, 18, 491–494. [Google Scholar] [CrossRef] [Green Version]
- Ganry, O.; Boche, T. Prevention practices and cancer screening among general practitioners in Picardy, France. Public Health 2005, 119, 1023–1030. [Google Scholar] [CrossRef] [PubMed]
- Kaplan, C.P.; Haas, J.S.; Pérez-Stable, E.J.; Des Jarlais, G.; Gregorich, S.E. Factors affecting breast cancer risk reduction practices among California physicians. Prev. Med. 2005, 41, 7–15. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, K.; Quistberg, D.A.; Micco, E.; Domchek, S.; Guerra, C. Prescription of Tamoxifen for Breast Cancer Prevention by Primary Care Physicians. Arch. Intern. Med. 2006, 166, 2260–2265. [Google Scholar] [CrossRef] [Green Version]
- Collier, R. American Medical Association membership woes continue. Can. Med. Assoc. J. 2011, 183, E713–E714. [Google Scholar] [CrossRef] [Green Version]
- Jbilou, J.; Halilem, N.; Blouin-Bougie, J.; Amara, N.; Landry, R.; Simard, J. Medical genetic counseling for breast cancer in primary care: A synthesis of major determinants of physicians’ practices in primary care settings. Public Health Genom. 2014, 17, 190–208. [Google Scholar] [CrossRef] [PubMed]
- Smith, S.G.; Side, L.; Meisel, S.F.; Horne, R.; Cuzick, J.; Wardle, J. Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation. Public Health Genom. 2016, 19, 239–249. [Google Scholar] [CrossRef] [PubMed]
- Smith, S.G.; Foy, R.; McGowan, J.A.; Kobayashi, L.C.; de Censi, A.; DeCensi, A.; Brown, K.; Side, L.; Cuzick, J. Prescribing tamoxifen in primary care for the prevention of breast cancer: A national online survey of GPs’ attitudes. Br. J. Gen. Pract. 2017, 67, e414–e427. [Google Scholar] [CrossRef]
- Collins, I.M.; Steel, E.; Mann, G.B.; Emery, J.D.; Bickerstaffe, A.; Trainer, A.; Butow, P.; Pirotta, M.; Antoniou, A.C.; Cuzick, J.; et al. Assessing and managing breast cancer risk: Clinicians’ current practice and future needs. Breast 2014, 23, 644–650. [Google Scholar] [CrossRef]
- Harris, H.; Nippert, I.; Julian-Reynier, C.; Schmidtke, J.; van Asperen, C.; Gadzicki, D.; Tibben, A.; Evans, D.G. Familial breast cancer: Is it time to move from a reactive to a proactive role? Fam. Cancer 2011, 10, 501–503. [Google Scholar] [CrossRef]
- Meaney-Delman, D.; Bellcross, C.A. Hereditary breast/ovarian cancer syndrome: A primer for obstetricians/gynecologists. Obstet. Gynecol. Clin. N. Am. 2013, 40, 475–512. [Google Scholar] [CrossRef]
- Archer, S.; Babb de Villiers, C.; Scheibl, F.; Carver, T.; Hartley, S.; Lee, A.; Cunningham, A.P.; Easton, D.F.; McIntosh, J.G.; Emery, J.; et al. Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study. PLoS ONE 2020, 15, e0229999. [Google Scholar] [CrossRef] [Green Version]
- Lo, L.L.; Collins, I.M.; Bressel, M.; Butow, P.; Emery, J.; Keogh, L.; Weideman, P.; Steel, E.; Hopper, J.L.; Trainer, A.H.; et al. The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. JMIR Form. Res. 2018, 2, e24. [Google Scholar] [CrossRef] [PubMed]
- Rainey, L.; van der Waal, D.; Jervaeus, A.; Donnelly, L.S.; Evans, D.G.; Hammarström, M.; Hall, P.; Wengström, Y.; Broeders, M.J.M. European women’s perceptions of the implementation and organisation of risk-based breast cancer screening and prevention: A qualitative study. BMC Cancer 2020, 20, 247:1–247:11. [Google Scholar] [CrossRef] [PubMed]
- Esquivel-Sada, D.; Lévesque, E.; Hagan, J.; Knoppers, B.M.; Simard, J. Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives. Healthc. Policy 2019, 15, 39–54. [Google Scholar] [CrossRef] [PubMed]
- Warr, W.; Aveyard, P.; Albury, C.; Nicholson, B.; Tudor, K.; Hobbs, R.; Roberts, N.; Ziebland, S. A systematic review and thematic synthesis of qualitative studies exploring GPs’ and nurses’ perspectives on discussing weight with patients with overweight and obesity in primary care. Obes. Rev. 2021, 22, e13151. [Google Scholar] [CrossRef]
- Johnston, S.; Liddy, C.; Hogg, W.; Donskov, M.; Russell, G.; Gyorfi-Dyke, E. Barriers and facilitators to recruitment of physicians and practices for primary care health services research at one centre. BMC Med. Res. Methodol. 2010, 10, 109:1–109:8. [Google Scholar] [CrossRef] [Green Version]
Characteristic | Number of Studies |
---|---|
Year of publication | |
1997–2004 | 7 |
2005–2012 | 9 |
2013–2020 | 11 |
Study country | |
USA | 14 |
UK | 5 |
Switzerland | 2 |
Multiple countries * | 2 |
France | 1 |
Canada | 1 |
Belgium | 1 |
Australia | 1 |
Sample size (n) | |
1–250 | 12 |
251–500 | 8 |
501–750 | 3 |
751–1000 | 2 |
>1000 | 2 |
Study population | |
Physicians only | 16 |
Mixed 1 | 5 |
Physicians and nursing staff | 4 |
Nursing staff only | 2 |
Study outcomes | |
Risk assessment | 24 |
Primary prevention | 9 |
% women in provider cohort | |
0–25 | 1 |
26–50 | 11 |
51–75 | 10 |
76–100 | 0 |
Not reported | 5 |
Tasks | Percentage Reporting Primary Care Responsibility [Mean and Range Reported if Multiple Values] | Associations with Perceived Roles |
---|---|---|
Breast cancer risk assessment | ||
Taking or documenting a family history [31,38,39] | 92.7 [89.0–98.0] | |
Providing counselling regarding familial risk [38,39] | 83.0 [81.0–85.0] | |
Providing follow up support after genetic testing [37,38] | 79.7 [66.8–92.5] | Country: One study recruited participants from four European countries (UK, France, Germany and the Netherlands). The majority of GPs from all four countries agreed that providing support after breast cancer testing was a primary care responsibility. However, the proportions varied significantly; the highest proportion was reported by the GPs from France (86.1%) and the lowest by the GPs from the UK (57.2%) [37] |
Obtaining informed consent before genetic testing [38,39] | 77.3 [67.0–87.5] | |
Identifying families at risk [38,39] | 72.0 [58.0–86.0] | |
Calculating breast cancer risk [31] | 62.0 | |
Informing about breast cancer genetic testing [37,39] | 61.5 [47.0–76.0] | Country: GPs from France were significantly more likely to assume responsibility for informing patients about breast cancer genetic testing in comparison to GPs from Germany, the Netherlands and the UK (56.2% vs. 46.6%, 41.7% and 41.6%) [37] |
Counseling women about breast density [40] | 43.0 | |
Explaining the inheritance pattern of familial breast cancer [37] | 42.7 | Country: GPs from France were significantly more likely to assume responsibility for explaining the inheritance pattern of familial breast cancer in comparison to GPs from Germany, the Netherlands and the UK (63.6% vs. 30%, 49.7% and 33.8%) [37] |
Disclosing breast cancer genetic test results [37,39] | 37.2 [27.4–47.0] | Country: GPs from Germany were significantly more likely to assume responsibility for disclosing breast cancer genetic test results in comparison to GPs from France, the Netherlands and the UK (43.7% vs. 23.5%, 11.6% and 16.9%) [37] |
Primary prevention | ||
Writing ongoing prescriptions for risk-reducing medications [41] | 97.9 | |
Providing options for prevention and early detection of breast cancer [38] | 86.0 | |
Initiating discussion of risk-reducing medications [41] | 75.0 | |
Writing first prescription for risk-reducing medications [41] | 31.3 | |
Breast cancer risk reduction with chemopreventive agents [31] | 18.0 | Sex: Males more likely to agree that breast cancer risk reduction with chemopreventive agents was a primary care provider’s responsibility than females (28% compared to 10%) [31] |
Themes | Percentage Endorsing Barrier [Mean and Range Reported if Multiple Values] | Associations with Barriers |
---|---|---|
Insufficient education/training [31,41,44,46] | 45.2 [20.0–82.1] | |
Discomfort discussing breast density [35,47,48] | 36.9 [11.7–81.5] | Training level: Internal medicine providers more likely to agree that they were comfortable counselling women about breast density compared to primary care residents (38% compared to 0%) [35] |
Discomfort conducting breast cancer risk assessment [46,49,50] | 30.9 [29.3–33.5] | Specialty: Women’s health providers more likely to respond that they were ‘very comfortable/comfortable’ with using a breast cancer risk assessment tool compared to other primary care providers (38% compared to 14%) [46] |
More immediate issues to discuss during consultation [31] | 25.0 | |
Insufficient provisions to conduct breast cancer risk assessment effectively (e.g., tools, patient information etc.) [31,41,44,46,51] | 20.6 [11.0–40.0] | |
Perceived lack of impact on patient management [44,46] | 16.8 [7.9–25.6] | |
Low perceived utility and acceptability of genetic testing for determining breast cancer risk [36,52] | 14.0 [5.1–22.9] | |
Concern that risk prediction models are not accurate enough [51] | 13.0 | |
Do not see patients for whom risk assessment is indicated [44,46] | 12.5 [7.9–17] | |
Concern about creating unnecessary anxiety/worry for many women [51] | 7.9 [2.0–13.7] | |
Assessment of breast cancer risk is not part of routine practice [41] | 7.0 | |
Perceived lack of primary care responsibility [46] | 5.9 | |
Reluctance to assess risk because a woman at low risk of breast cancer might decide not to undergo mammography screening [51] | 6.0 |
Tasks | Percentage Reporting Confidence [Mean and Range Reported if Multiple Values] | Associations with Confidence |
---|---|---|
Taking a family history [42,53,54] | 63.5 [60.7–65.5] | Training: Nurses who had attended training about genetic issues in the 12 months were more likely to report being ‘confident or very confident’ compared with those who did not attend (72% compared to 59%) [42] |
Reassuring low-risk patients [42,53,54] | 58.8 [46.0–67.7] | Training: Confidence providing reassurance for those at low risk of breast cancer was significantly associated with attending training about genetic issues [42] |
Making a basic risk assessment [42,53] | 57.4 [53.9–60.8] | |
Ability to provide information to patients about BRCA cancer risks and inheritance [55] | 55.8 [50.0–61.6] | |
Ability to provide information to patients about BRCA test methods and interpretation [55] | 39.6 [37.2–41.9] | |
Ability to answer patients’ questions during a consultation about risk [54] | 23.2 | |
Ability to use Gail scores to identify women at increased risk for breast cancer [31] | 8.6 |
Behaviours | Percentage Reporting Behaviour [Mean and Range Reported if Multiple Values] | Associations with Behaviour |
---|---|---|
Breast cancer risk assessment | ||
Discussing family history as part of a woman’s health history [56] | 92.6 | |
Considering a discussion of family history with a woman consulting with concerns about breast cancer risk [57] | 90.4 | |
Collecting family history during routine clinical practice [31,46,58] | 86.3 [71.0–95.0] | Training level: Staff more likely to report ‘usually or always’ assessing family history during routine visits compared to residents (79% compared to 58%) [31] |
Discussing family history to assess breast cancer risk [45,49] | 67.0 [37.1–96.9] | |
Collecting family history during new patient appointment [42,43] | 58.9 [48.4–69.3] | |
Using multi-factorial breast cancer risk assessment tools [45,47,50] | 33.1 [22.4–50.9] | Specialty: Obstetric-gynaecologists more likely to report using breast cancer risk assessment tools compared to family medicine physicians and internists to (67.2% vs. 44.0% and 41.7%) [45] |
Assessing risk using the Gail model [31,44,49] | 16.8 [3.0–40.9] | Training level: Attending physicians more likely to report use of the Gail model compared to resident physicians [44] Specialty: Gynaecology more likely to report use of the Gail model compared to family medicine and internal medicine physicians (60% vs. 33.3% and 36.9%) [44] |
Themes | Percentage Endorsing Barrier [Mean and Range Reported if Multiple Values] | Associations with Barriers |
---|---|---|
Discomfort prescribing risk-reducing medication [44,46] | 75.0 [70.1–79.8] | Specialty: Women’s health providers more likely to respond that they were ‘very comfortable/comfortable’ with prescribing risk-reducing medication compared to other primary care providers (9% compared to 2%) [46] |
Concern about prescribing off-label (unlicensed) medication [50] | 58.1 | |
Never seen a patient for whom risk-reducing medications are indicated [44,46] | 39.6 [18.4–60.7] | |
Insufficient education/training [41,46,50,59] | 34.6 [13.9–72.0] | |
Insufficient provisions to discuss risk-reducing measures effectively (e.g., time, patient information, resources etc.) [41,44,46,50,59,60] | 22.7 [6.1–50] | Specialty: Family and internal medicine physicians more likely to report time constraints as a barrier than obstetrician-gynaecologists (45.8% and 46.5% vs. 31.3%, respectively) [59] |
More immediate issues to discuss during consultation [41] | 18.0 | |
Doubts about effectiveness of risk-reducing medications (e.g., belief in ability to reduce risk and mortality, perceiving the evidence base as controversial) [41,44,45,50,60] | 15.4 [1.0–31.5] | |
Forgetting to discuss risk-reducing medications [41] | 14.0 | |
Believing that the risks of prescribing risk-reducing medications outweigh the benefits [45,50,60] | 13.5 [6.5–20.5] | Specialty: Obstetrician-gynaecologists less likely to agree that the evidence of preventive agents reducing breast cancer risk is controversial compared to family medicine physicians and internists (22.8% vs. 37.6% and 34.0% respectively) [45] Obstetrician-gynaecologists less likely to agree that the risk of endometrial cancer is too great to prescribe tamoxifen for breast cancer reduction compared to family medicine physicians and internists (14.8% vs. 18.4% and 18.8%) [45]. Obstetrician-gynaecologists less likely to agree that the risk of thromboembolic disease is too great to prescribe preventive agents for breast cancer reduction compared to family medicine physicians and internists (10.8% vs. 26.0% and 24.8%) [45] |
Women’s perceived lack of interest and knowledge about risk reduction [41,59] | 12.0 [1.0–27.0] | |
Perceived lack of primary care responsibility [41,46,59] | 11.6 [4.0–23.9] | |
Lack of incentives for discussing risk reducing measures [41,59] | 8.3 [3.0–13.6] | |
Discomfort prescribing a ‘cancer drug’ to healthy women [41] | 4.0 | |
Concern about increasing patient’s worry about breast cancer [41] | 2.0 | |
Perceived lack of impact on patient management [46] | 1.2 |
Themes | Percentage Endorsing Facilitator [Mean and Range Reported if Multiple Values] |
---|---|
Availability of provisions to discuss risk-reducing options more effectively (e.g., tools and guidelines to identify suitable patients, better patient education materials etc.) [41,59] | 61.6 [33.0–88.0] |
Knowing some risk-reducing medications are available at a Government-subsidised price [41] | 54.0 |
Endorsement as part of role by a professional body [41] | 53.0 |
More education/training [59] | 52.0 [34.5–69.4] |
Patient has indications of increased breast cancer risk [41] | 46.3 [36.0–54.0] |
Understanding the benefits of primary prevention [41,59] | 44.0 [14.0–59.1] |
Peer support [41] | 41.7 [27.0–64.0] |
Believing that the benefits of preventive agents in breast cancer outweigh the risks [45,50] | 37.6 [12.4–62.8] |
Easier to discuss risk-reducing medications than bilateral mastectomy [41] | 32.0 |
Yes | Somewhat | No | Cannot Tell | |||||
---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | |
Is the sampling strategy relevant to address the research question? | 6 | 21 | 17 | 59 | 3 | 10 | 3 | 10 |
Is the sample representative of the target population? | 9 | 31 | 5 | 17 | 7 | 24 | 8 | 28 |
Are the measurements appropriate? | 0 | 0 | 18 | 62 | 0 | 0 | 11 | 38 |
Is the risk of nonresponse bias low? | 3 | 10 | 11 | 38 | 12 | 41 | 3 | 10 |
Is the statistical analysis appropriate to answer the research question? | 23 | 79 | 2 | 7 | 0 | 0 | 4 | 14 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bellhouse, S.; Hawkes, R.E.; Howell, S.J.; Gorman, L.; French, D.P. Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours. Cancers 2021, 13, 4150. https://doi.org/10.3390/cancers13164150
Bellhouse S, Hawkes RE, Howell SJ, Gorman L, French DP. Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours. Cancers. 2021; 13(16):4150. https://doi.org/10.3390/cancers13164150
Chicago/Turabian StyleBellhouse, Sarah, Rhiannon E. Hawkes, Sacha J. Howell, Louise Gorman, and David P. French. 2021. "Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours" Cancers 13, no. 16: 4150. https://doi.org/10.3390/cancers13164150
APA StyleBellhouse, S., Hawkes, R. E., Howell, S. J., Gorman, L., & French, D. P. (2021). Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours. Cancers, 13(16), 4150. https://doi.org/10.3390/cancers13164150